DAY 1 - THURSDAY MAY 28th 2020


 

8:00 am

Registration and coffee

8:45 am

Welcome speech


 

SESSION I - ADVANCED CELL THERAPY

9:00 am

Reprogramming immune cells with CRISPR
Alexander Marson, University of California, San Francisco, USA

9:30 am

Effector CAR-T cells
Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA

10:00 am

CAR-Treg in transplantation and autoimmunity
Ignacio Anegon, Inserm UMR 1064 - Center for Research in Transplantation and Immunology, LabEx IGO, FOCIS Center of Excellence, Nantes University

10:30 am

COFFEE BREAK

11:00 am

Human tolerogenic dendritic cells used in clinic to regulate immune responses through lactate synthesis
Aurélie Moreau, Inserm UMR 1064 - Center for Research in Transplantation and Immunology, University of Nantes / Nantes University Hospital, France

11:30 am

Selected communications


 


 

12:00 am

LUNCH BREAK & Poster VIEWING session


 

SESSION II - TISSUE MICROENVIRONMENT

2:00 pm

TIGIT and its cellular and bacterial ligands: new checkpoints for cancer immune therapy
Ofer Mandelboim, Institute of Medical Research Israel-Canada (IMRIC), University of Jerusalem, Israel

2:30 pm

Evolution of a Stromal-Immune Axis in Cancer Immunology and Immunotherapy
Shannon J. Turley, Department of Cancer Immunology, Genentech, South San Francisco, CA, USA

3:00 pm
  Inflammation and Inflammasome
  Renato Monteiro, Center for Research on Inflammation - INSERM U 1149 & CNRS
  ERL8252 / Paris Diderot Faculty of Medicine

3:30 pm

COFFEE BREAK

4:00 pm

Tissue Macrophages
Massimo Locati - Department of Medical Biotechnologies and Translational Medicine, University of Milan, Italy (tbc)

4:30 -
5 pm

Selected communications

DAY 2 - FRIDAY MAY 29th 2020

 

8:00 am

Coffee

8:30 am

Keynote speech - New immunotherapies in cancer and autoimmunity

Jeff Bluestone,  UCSF and Parker Foundation, USA


 

SESSION III - BIOREAGENTS

9:00 am

Harnessing Innate Immunity in Cancer Therapy

Eric Vivier, Aix Marseille University, APHM, CNRS, INSERM, CIML / Hôpital de la Timone, Marseille-Immunopole / Innate Pharma Research Laboratories, Marseille, France

9:30 am

IL-2-based strategies targeting Tregs to stimulate or dampen the immune response

Eliane Piaggio, Translational immunotherapy team U938, Institut Curie, Paris

10:00 am

Targeting Trained Immunity in Organ Transplantation

Jordi Ochando,  Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.

10:30 am

COFFEE BREAK

11:00 am

Oncolytic activity of attenuated Measles virus and the defects in the type I interferon response in cancer

Jean-François Fonteneau, CRCINA (INSERM U1232), Nantes

11:30 am

Selected communications

 

12:00 am

LUNCH BREAK & Poster VIEWING session


 

SESSION IV - NEW HORIZONS

1:30 pm

Targeting common epithelial malignancies with TCR engineered lymphocytes specific for 'public' neoantigens

Christopher Klebanoff, Memorial Sloan Kettering Cancer Center and the Parker Institute for Cancer Immunotherapy, New York, USA

2:00 pm

Single cell new technologies - Mikael Pittet  (tbc)

2:30 pm

High content tissue analysis - Johanna Wagner (tbc)

3:00 pm

COFFEE BREAK

3:30 pm

Mesenchymal stromal cell heterogeneity: implication for their clinical application

Karin Tarte, Inserm U1236, Université Rennes, CHU Rennes

4:00 pm

Organoids  - Robert Lanza, Astellas Institute for Regenerative Medicine, Marlborough, USA (tbc)

4:30 pm

Awarding ceremony (best oral presentation, best poster)